Breast cancer remains a major health problem in the United States and other industrialized nations in spite of recent advances in its detection and treatment. Significant progress has been made through decades of basic research and clinical trials, but many questions remain unanswered. The purpose of this chapter is to summarize current information on the treatment of early breast cancer (i.e., breast cancer in which all clinically apparent disease can be removed surgically). The other topics will be covered as much as they are relevant to therapeutic decision making. The treatment of locally advanced and metastatic breast cancer will be addressed in the next chapter.
KeywordsBreast Cancer Sentinel Node Breast Cancer Risk Clin Oncol Axillary Node Dissection
Unable to display preview. Download preview PDF.
- 1.Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24: S120–S135Google Scholar
- 6.American Joint Committee on Cancer (AJCC) (1997) Cancer staging manual, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
- 32.Assikis VJ, Jordan VC (1997) Risks and benefits of tamoxifen therapy. Oncology (Huntingt) 11:S21–S23Google Scholar
- 34.Early Breast Cancer Trialists’ Collaborative Group (2000) Ovarian ablation in early breast cancer: Update. Cochrane Database Syst Rev (3) CD000485Google Scholar
- 37.Fisher B, Dignam J, Mamounas E et al (1996) Sequential methotrexate and fluorouracil for the treatment of nodenegative breast cancer patients with estrogen receptor-negative tumors; eight-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 14:1982–1992PubMedGoogle Scholar
- 39.Fisher B, Brown AM, Dimitrov MV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive breast cancer patients with tamoxifen-nonresponsive tumors: results from (NSABP) B-15. J Clin Oncol 8:1483–1496PubMedGoogle Scholar
- 41.Henderson IC, Berry D, Demetri G et al (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC) (abstract no. 390A). Proc Am Soc Clin Oncol 17:101AGoogle Scholar
- 47.Breast Cancer Surveillance Expert Panel (1997) Recommended breast cancer surveillance guidelines. J Clin Oncol 15:2149–2156Google Scholar